Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Diabetes Right
  3. Mounjaro™ (tirzepatide) injection Right
  4. What were the Mounjaro™ (tirzepatide) discontinuation rates in the SURPASS clinical trial program?
Search Mounjaro (tirzepatide) injection (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Mounjaro™ (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What were the Mounjaro™ (tirzepatide) discontinuation rates in the SURPASS clinical trial program?

In the SURPASS-1 to -5 trials in adults with type 2 diabetes, overall treatment discontinuation rates ranged from 8.3% to 21.5% and discontinuation rates due to adverse events ranged from 3.3% to 11.2% in the tirzepatide-treatment arms.

US_cFAQ_TZP057_SURPASS_STUDY_DRUG_DISCONTINUATION
cFAQ
cFAQ
US_cFAQ_TZP057_SURPASS_STUDY_DRUG_DISCONTINUATION
en-US

See important safety information, including boxed warning, in the attached prescribing information.

Study Drug Discontinuation in the SURPASS Clinical Trial Program

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1

The efficacy and safety of tirzepatide were evaluated in people with T2D in the SURPASS clinical trial program.2-6

In the SURPASS-1 to -5 trials in adults with type 2 diabetes, overall treatment discontinuation rates ranged from 8.3% to 21.5% in the tirzepatide treatment arms. In these patients, adverse events were the most common reason for discontinuation of treatment.2-6 

Rates of study drug discontinuation and of study drug discontinuation due to adverse event by treatment arm in SURPASS-1 to -5 are described in Summary of Study Drug Discontinuation in the SURPASS-1 to -5 Studies.2,3,6,7

Summary of Study Drug Discontinuation in the SURPASS-1 to -5 Studies2,3,5-7

Parameter, n/N (%)​a

Tirzepatide 5 mg

Tirzepatide 10 mg​

Tirzepatide 15 mg​

Comparatorb

Study drug discontinuation​

SURPASS-1

11/121 (9.1)​

12/121 (9.9)​

26/121 (21.5)​

17/115 (14.8)​

SURPASS-2

39/471 (8.3)​

58/469 (12.4)​

62/470 (13.2)​

41/469 (8.7)​

SURPASS-3

42/358 (11.7)​

66/360 (18.3)​

59/359 (16.4)​

40/360 (11.0)​

SURPASS-4

51/329 (15.5)

44/330 (13.3)

55/338 (16.3)

139/1005 (13.8)

SURPASS-5

11/116 (9.5)​

14/119 (11.8)​

22/120 (18.3)​

4/120 (3.3)​

Study drug discontinuation due to adverse event

SURPASS-1

4/121 (3.3)

6/121 (4.9)

8/121 (6.6)

3/115 (2.6)

SURPASS-2

24/471 (5.1)

36/469 (7.7)

37/470 (7.9)

18/469 (3.8)

SURPASS-3

26/358 (7.3)

35/360 (9.7)

39/359 (10.9)

5/360 (1.4)

SURPASS-4

24/329 (7.3)

26/330 (7.9)

30/338 (8.9)

19/1005 (1.9)

SURPASS-5

7/116 (6.0)

10/119 (8.4)

13/120 (10.8)

3/120 (2.5)

Abbreviation: mITT = modified intention-to-treat.

Note: Primary endpoint for SURPASS-1, SURPASS-2, and SURPASS-5 was at 40 weeks and for SURPASS-3 and SURPASS-4 was at 52 weeks.

aData are n (%); all randomized population. N = all randomly assigned participants who took at least 1 dose of study drug (mITT population).

bComparator was placebo in SURPASS-1 and SURPASS-5 for 40 weeks. Comparator was semaglutide 1 mg once weekly in SURPASS-2 for 40 weeks. Comparator was titrated insulin degludec in SURPASS-3 for 52 weeks. Comparator was titrated insulin glargine in SURPASS-4 for 52 weeks.

SURPASS Study Summaries

SURPASS-1 was a 40-week, phase 3, double-blind, randomized study of tirzepatide 5, 10, and 15 mg once weekly as monotherapy compared with placebo in 478 adults with T2D inadequately controlled with diet and exercise alone.2

SURPASS-2 was a 40-week, phase 3, open-label, randomized study of tirzepatide 5, 10, and 15 mg once weekly compared with semaglutide 1 mg once weekly as add-on therapy to metformin in 1879 adults with T2D.3

SURPASS-3 was a 52-week, phase 3, open-label study of tirzepatide 5, 10, and 15 mg once weekly compared with titrated insulin degludec daily in 1444 adults with T2D inadequately controlled on metformin with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.4

SURPASS-4 was a 52-week, phase 3, open-label, randomized study comparing tirzepatide 5, 10, and 15 mg once weekly with titrated insulin glargine once daily added to at least 1 and up to 3 oral antihyperglycemic medications (OAMs) (metformin, sulfonylureas, or SGLT-2 inhibitors) in 2002 adults with T2D and increased cardiovascular risk.5

SURPASS-5 was a 40-week, phase 3, double-blind, randomized study of tirzepatide 5, 10, and 15 mg once weekly compared with placebo in 475 adults with T2D, as add-on to titrated insulin glargine with or without metformin.6

Enclosed Prescribing Information

MOUNJARO™ (tirzepatide) injection, for subcutaneous use, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

2Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. https://doi.org/10.1016/S0140-6736%2821%2901324-6

3Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519

4Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598. https://doi.org/10.1016/S0140-6736(21)01443-4

5Del Prato S, Kahn SE, Pavo I, et al; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. https://doi.org/10.1016/S0140-6736(21)02188-7

6Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534-545. https://doi.org/10.1001/jama.2022.0078

7Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598. https://doi.org/10.1016/S0140-6736(21)01443-4

Date of Last Review: February 02, 2023

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly